Tatsuya Ide

Tatsuya Ide

Auto-generated profile, based on publicly available information

Tatsuya Ide

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2012 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
HSHiromi Sawai
Hiromi Sawai
NNNao Nishida
Nao Nishida
HMHamdi Mbarek
Hamdi Mbarek
KMKoichi Matsuda
Koichi Matsuda
YMYoriko Mawatari
Yoriko Mawatari
Katsushi TokunagaKatsushi Tokunaga
Katsushi Tokunaga
A recent genome-wide association study (GWAS) using chronic HBV (hepatitis B virus) carriers with and without hepatocellular carcinoma (HCC) in five independent Chinese populations found that one SNP (rs17401966) in KIF1B was associated with susceptibility to HCC. In the present study, a total of 580 HBV-derived HCC cases and 1351 individuals with chronic hepatitis B (CHB) or asymptomatic carrier (ASC) were used for replication studies in order to evaluate the reported association with HBV-derived HCC in other East Asian populations. We did not detect any associations between rs17401966 and HCC in the Japanese cohorts (replication 1: OR = 1.09, 95 % CI = 0.82-1.43; replication 2: OR = 0.79, 95 % CI = 0.54-1.15), in the Korean cohort (replication 3: OR = 0.95, 95 % CI = 0.66-1.36), or in the Hong Kong Chinese cohort (replication 4: OR = 1.17, 95 % CI = 0.79-1.75). Meta-analysis using these cohorts also did not show any associations with P = 0.97. None of the replication cohorts showed associations between rs17401966 and HBV-derived HCC. This may be due to differences in the genetic diversity among the Japanese, Korean and Chinese populations. Other reasons could be the high complexity of multivariate interactions between the genomic information and the phenotype that is manifesting. A much wider range of investigations is needed in order to elucidate the differences in HCC susceptibility among these Asian populations.

30 October 2015 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
AHAkiko Hisamochi
Akiko Hisamochi
MKMasayoshi Kage
Masayoshi Kage
TITatsuya Ide
Tatsuya Ide
TATeruko Arinaga-Hino
Teruko Arinaga-Hino
KAKEISUKE AMANO
KEISUKE AMANO
TTTakuji Torimura
Takuji Torimura

18 December 2008 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TITatsuya Ide
Tatsuya Ide
THTeruko Hino
Teruko Hino
KOKei Ogata
Kei Ogata
IMIchiro Miyajima
Ichiro Miyajima
RKReiichiro Kuwahara
Reiichiro Kuwahara
MSMichio Sata
Michio Sata
The treatment of patients with hepatitis C virus (HCV) genotype 1 with peginterferon plus ribavirin treatment for more than 48 weeks demonstrated high sustained virological response (SVR) rates. Although many studies extended the duration of therapy from 48 weeks to 72 weeks, the optimal duration has not yet been determined. A total of 113 genotype 1b patients with high viral load were randomized at baseline to the standard (n=56) or extended (n=57) treatment group. The standard group patients received 48 weeks of peginterferon plus ribavirin treatment. In the extended group, the treatment was performed for 44 weeks after patients became negative for HCV RNA (total duration 48–68 weeks). The SVR rate of the standard and extended group was 36% (20 of 56) and 53% (30 of 57; P=0.07). However, the extended group patients who became negative for HCV RNA between weeks 16 and 24 had a significantly higher SVR rate (78%; 7 of 9) than that of standard group (9%, 1 of 11; P=0.005). The predictive factors for the SVR were the treatment regimen (the standard vs. extended treatment) and the time to HCV RNA negative–status. The extended treatment significantly increased the SVR rate in patients who were HCV RNA negative at 16–24 weeks.

17 November 2003 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
RKReiichiro Kuwahara
Reiichiro Kuwahara
RKRyukichi Kumashiro
Ryukichi Kumashiro
SMShiro Murashima
Shiro Murashima
KOKei Ogata
Kei Ogata
KTKazuo Tanaka
Kazuo Tanaka
MSMichio Sata
Michio Sata

1 August 2003 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
YTYoshiyasu Tsuji
Yoshiyasu Tsuji
RKRyukichi Kumashiro
Ryukichi Kumashiro
KIKunihide Ishii
Kunihide Ishii
TATeruko Arinaga
Teruko Arinaga
YSYoshihiro Sakamoto
Yoshihiro Sakamoto
MSMichio Sata
Michio Sata

1 January 2010 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
KNKan Nakamura
Kan Nakamura
EKEiji Kawasaki
Eiji Kawasaki
NANorio Abiru
Norio Abiru
OJOzora Jo
Ozora Jo
KFKeiko Fukushima
Keiko Fukushima
KEKatsumi Eguchi
Katsumi Eguchi
Interferon-alpha (IFN-α) is widely used in the treatment of viral hepatitis, however, it is known that IFN-α therapy may induce type 1 diabetes. We report here on two cases of chronic viral hepatitis C who developed autoimmune type 1 diabetes during Peg-IFN-α plus ribavirin (RBV) therapy. Case 1: a 48-year-old male with chronic hepatitis C with chronic thyroiditis. The patient’s plasma glucose level was normal and anti-islet autoantibody tests were negative before Peg-IFN-α+RBV therapy. The emergence of glutamic acid decarboxylase 65 autoantibody (GAD65Ab) was observed after five months of treatment. Autoantibodies to insulin and insulinoma-associated antigen-2 (IA-2) also became positive. Eleven months later, thirst and polydipsia occurred with increased fasting plasma glucose level and the patient was diagnosed with type 1A diabetes. Zinc transporter-8 autoantibody (ZnT8Ab) was not detectable at any point. The patient has type 1 diabetes-susceptible HLA-DRB1-DQB1 haplotypes *0405-*0401 and *0901-*0303. Case 2: a 65-year-old male with chronic hepatitis C with type 2 diabetes on insulin treatment. GAD65Ab and IA-2Ab were negative before Peg-IFN-α+RBV therapy, however, nine months later, a single appearance of GAD65Ab was observed. After twelve months, his plasma glucose control worsened rapidly, and he was diagnosed with type 1A diabetes. IA-2Ab and ZnT8Ab were negative throughout the clinical course. His HLA-DRB1-DQB1 haplotypes were *0410-*0402 and *1407-*0503. Both cases showed a unique GAD65Ab epitope (amino acids 360-442). These clinical courses suggest that IFN-α therapy provoked acute islet autoimmunity and onset of type 1 diabetes. Therefore, during IFN-α therapy, patients should be closely monitored for the occurrence of type 1 diabetes.